SciELO - Scientific Electronic Library Online

 
vol.6 número16Importancia nutricional en el manejo de sarcopenia en adultos mayores índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Vive Revista de Salud

versión impresa ISSN 2664-3243

Resumen

ARTEAGA, Andrea Salinas. Pharmacologic treatment for pulmonary thromboembolism in patients with atrial fibrillation. Vive Rev. Salud [online]. 2023, vol.6, n.16, pp.354-375.  Epub 14-Feb-2023. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v6i16.231.

Atrial fibrillation is one of the most common cardiac arrhythmias. It affects 1 in 200 people between 40 and 50 years of age, but may affect more than 1 in 10 people in their 80s. Objective. To propose a pharmacological treatment guideline to prevent pulmonary thromboembolism in patients with atrial fibrillation with ventricular response. Materials and methods. The methods used were of theoretical level as historical-logical, modeling, hypothetical- deductive, dialectical, holistic-holographic and systemic-structural-functional. As empirical methods, the review of guidelines documents, clinical histories, surveys to physicians and pharmacists were applied, as well as scientific observation, the results were reflected in the review of the clinical histories of the 38 patients with a diagnosis of chronic atrial fibrillation. Results. The type of treatment is represented with a predominance of 24 patients taking anticoagulants (63.16%), most of the patients were not anti coagulated, anti coagulated patients (34.62%), also the proposal of a pharmacological treatment guide to avoid pulmonary thromboembolism in patients with atrial fibrillation with rapid ventricular response was elaborated, according to international standards to prevent thromboembolic complications of atrial fibrillation. Conclusions. Due to its increasing prevalence, the impact on survival, the quality of life of patients, the high health care costs involved in its treatment, and the incessant advance in new treatments for atrial fibrillation with rapid ventricular response, it is necessary to periodically update the evidence-based recommendations.

Palabras clave : Atrial Fibrillation; Thromboembolism; Evidence-Based Pharmacy Practice.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )